ArchivesMagazine - 05 Nov 2020The market is far too pessimistic on GlaxoSmithKline Investors are not giving the company any credit for the significant changes made to its structure and focus 05 November 2020|Great Ideas|by Martin Gamble Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email < Why it helps if chip stocks show some sizzle Yamana Gold boosts growth prospects with latest acquisition > Issue: 05 Nov 2020 - Page 14 | Contents Next: Yamana Gold boosts growth prospects with latest acquisition Previous: Why it helps if chip stocks show some sizzle Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email Martin Gamble Issue Contents Ask Tom Is it worth making up national insurance shortfall to get a state pension? Editor's View Big oil’s dividend dilemma Feature Amazon: Can it keep winning as lockdown resumes? What investors should do after the latest correction How paying off debt can transform a company’s share price First-time Investor Cash flow is a figure that can’t be fudged Funds Know your fund: Fidelity Global Special Situations isn’t giving up on value Great Ideas Buy this newly-listed gold giant for lower risk and high rewards The market is far too pessimistic on GlaxoSmithKline Microsoft still a long-run winner Rent collection builds at Stenprop Yamana Gold boosts growth prospects with latest acquisition News Stocks soar despite US election chaos with Congress gridlock likely How ‘Lockdown 2’ news impacted the markets Alibaba left with bloody nose as Ant IPO shelved at the 11th hour Horizon Discovery and LiDCO surge on agreed takeover bids New rules on ISAs to crimp demand for property funds Personal Finance Why fund investors are under-allocated to the US and does it matter? Russ Mould Why it helps if chip stocks show some sizzle
